

# ICE-LAP3, a Novel Mammalian Homologue of the *Caenorhabditis elegans* Cell Death Protein Ced-3 Is Activated during Fas- and Tumor Necrosis Factor-induced Apoptosis\*

(Received for publication, September 27, 1995, and in revised form, November 28, 1995)

Hangjun Duan, Arul M. Chinnaiyan†, Peter L. Hudson§, John P. Wing§, Wei-Wu He§,  
and Vishva M. Dixit||

From the Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109 and  
§Human Genome Sciences, Inc., Rockville, Maryland 20850-3338

Members of the ICE/ced-3 gene family have been implicated as components of the cell death pathway. Based on similarities with the structural prototype interleukin-1 $\beta$ -converting enzyme (ICE), family members are synthesized as proenzymes that are proteolytically processed to form active heterodimeric enzymes. In this report, we describe a novel member of this growing gene family, ICE-LAP3, which is closely related to the death effector Yama/CPP32/Apopain. Pro-ICE-LAP3 is a 35-kDa protein localized to the cytoplasm and expressed in a variety of tissues and cell lines. Overexpression of a truncated version of ICE-LAP3 (missing the pro-domain) induces apoptosis in MCF7 breast carcinoma cells. Importantly, upon receipt of a death stimulus, endogenous ICE-LAP3 is processed to its subunit forms, suggesting a physiological role in cell death. This is the first report to demonstrate processing of a native ICE/ced-3 family member during execution of the death program and the first description of the subcellular localization of an ICE/ced-3 family member.

Apoptosis, or programmed cell death, is essential for the development and homeostasis of multicellular organisms (1). It is an active form of cellular suicide encoded by an endogenous program that can be triggered by either internal or external cues. The morphological alterations of programmed cell death include cellular shrinkage, membrane blebbing, and chromatin condensation (2). Derangements of apoptosis contribute to the pathogenesis of several human diseases including cancer, acquired immunodeficiency syndrome, and neurodegenerative disorders (3–5).

Despite its biological importance, the molecular mechanism behind apoptosis remains to be defined. Recently, systematic genetic analysis of *Caenorhabditis elegans* has identified three genes (ced-3, ced-4, and ced-9) that are important in the regulation of nematode cell death. The proteins encoded by ced-3

and ced-4 are required for all somatic cell deaths that occur during the development of *C. elegans* (6). Mutations of ced-3 and ced-4 abolish the apoptotic capability of cells that normally die during development (7). By contrast, ced-9, which encodes a protein that is homologous to the mammalian gene bcl-2, functions to suppress somatic cell death in the nematode (8). The function of ced-9 can be partially substituted by ectopic expression of bcl-2 (9). These results suggest that components of the apoptotic machinery are conserved throughout evolution and that mammalian counterparts of ced-3 and ced-4 may play an important role in the mammalian cell death pathway. To date, no homologues of ced-4 have been identified. By contrast, numerous relatives of ced-3 have been characterized, comprising a new gene family of cysteine proteases.

The first mammalian homologue of ced-3 identified was interleukin-1 $\beta$ -converting enzyme (ICE)<sup>1</sup> (10), a cysteine protease involved in the processing and activation of pro-interleukin-1 $\beta$  to an active cytokine (11, 12). Overexpression of ICE or Ced-3 in Rat-1 cells induced apoptosis, suggesting that ICE may act as the functional mammalian homologue of Ced-3 (13). However, later studies refute this possibility, since ICE-deficient mice develop normally and express no overt defects in apoptosis, except possibly in the Fas pathway (14, 15). Furthermore, apoptotic extracts prepared from chicken DU249 cells failed to cleave the primary substrate of ICE, pro-interleukin-1 $\beta$  (16). Instead, an ICE-like activity in these extracts, termed prICE, cleaved the nuclear enzyme poly(ADP-ribose) polymerase (PARP) into characteristic fragments (16). Purified ICE failed to cleave PARP (16, 17), suggesting that prICE was distinct from ICE. These observations, along with others, suggest that an ICE-like enzyme, rather than ICE itself, plays a role in the mammalian cell death pathway.

Five members of the ICE/Ced-3 family have been recently identified and include Nedd-2/ICH1 (18, 19), Yama/CPP32/Apopain (17, 20, 21), TX/ICH2/ICE rel-II (22–24), ICE rel-III (22), and Mch2 (25). All family members share sequence homology with ICE/Ced-3 and contain an active site QACRG pentapeptide in which the cysteine residue is catalytic. Overexpression of these proteins in a variety of cells causes apoptosis.

Among the ICE/Ced-3 family members thus far cloned, evidence is growing that Yama may act as a distal effector of the apoptotic machinery. Yama has been shown to cleave the death substrate PARP, in addition to being inhibitable by the cowpox serpin, CrmA (17). Activated Yama (or Apopain), comprised of p17 and p12 subunits, was purified from cell extracts using a

\* This work was supported by National Institutes of Health Grant CA64803. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>†</sup> The nucleotide sequence(s) reported in this paper has been submitted to the GenBank™/EMBL Data Bank with accession number(s) U39613.

<sup>||</sup> Fellow of the Medical Scientist Training Program, supported by the National Institutes of Health Experimental Immunopathology Training Grant.

<sup>1</sup> Established Investigator of the American Heart Association. To whom correspondence should be addressed: Dept. of Pathology, University of Michigan Medical School, 1301 Catherine St., Box 0602, Ann Arbor, MI 48109. Tel.: 313-747-2921; Fax: 313-764-4308; E-mail: vmdixit@umich.edu.

<sup>1</sup> The abbreviations used are: ICE, interleukin-1 $\beta$ -converting enzyme; PARP, poly(ADP-ribose) polymerase; PCR, polymerase chain reaction; TNF, tumor necrosis factor; PBS, phosphate-buffered saline.

## Characterization of ICE-LAP3

tetrapeptide aldehyde inhibitor corresponding to amino acids at the PARP cleavage site (21). Depletion of Yama from these extracts abrogated their apoptotic potential *in vitro* (21). This apoptotic activity could be restored by adding back purified Yama to the depleted extracts (21). Though the evidence is compelling that Yama serves as a functional mammalian homologue of Ced-3, one cannot exclude a role for other ICE/Ced-3 family members in the cell death pathway. For instance, Yama may be the distal effector of a proteolytic cascade that is comprised of (or activated by) other related family members. A precedent for this is the activation of Yama by purified ICE or granzyme B *in vitro* (17, 26). Alternatively, there may exist a redundant cell death pathway in which individual ICE/Ced-3 family members play a role.

Here we report the cloning and characterization of a novel member of the ICE/Ced-3 family designated ICE-LAP3 (for ICE-Like Apoptotic Protease 3) that is closely related to the death effector Yama. ICE-LAP3 is expressed in a variety of tissues and cell lines. Overexpression of ICE-LAP3 in MCF7 cells induces cell death, and mutation of the putative catalytic cysteine residue abolishes its apoptotic potential. Stimulation of the cytokine death receptors, Fas/APO-1 or TNFR-1, triggers processing of pro-ICE-LAP3 to active p20 and p12 subunits. Taken together, our results suggest that ICE-LAP3 is likely a cysteine protease that may have a role in cytokine-mediated cell death.

## MATERIALS AND METHODS

**Cloning of Human ICE-LAP3**—The cDNA corresponding to ICE-LAP3 was identified as a sequence homologous to ICE on searching the Human Genome Sciences private data base using established EST methods (27, 28).

**DNA Sequencing**—The sequence of ICE-LAP3 was confirmed by sequencing plasmid DNA template on both strands by the dideoxy chain termination method using modified T7 DNA polymerase (Sequenase, U.S. Biochemical Corp.). Sequence alignments were performed using DNASTAR Megalign software.

**Expression Constructs**—The p28 version of ICE-LAP3, which lacks the first 53 N-terminal amino acids that encode the putative pro-domain was generated by PCR and subcloned into the mammalian expression vector pcDNA3 (Invitrogen, San Diego, CA). The upstream PCR primer (CGGGGTACCGCCATGCCAGTGCTACATATCAGTAC) encoded an artificial initiator methionine within Kozak's consensus (*italics*) and a custom *Kpn*I restriction site (underlined). The downstream primer (GCTCTAGATTAGATGTAGCGGTATGTGCTTGAC-TGAAGTAGAGTTCC) encoded an AU1 epitope tag (DTYRYI; *italics*) and an in-frame stop codon (underlined). Alteration of the active site cysteine 184 to alanine was accomplished by site-directed mutagenesis employing a four-primer two-step PCR protocol as described previously (29). Sequences of the mutagenic oligonucleotides were as follows with the altered codon underlined: CAAACTCTTCTTCATTCAAGCTCGGTCTCGAG-GAGGGACCGAGCTTGATGA and TCATCAAGCTCGGTCTCGAG-CAGCCTGAATGAAGAAGACTTTC. The presence of the introduced mutation and fidelity of PCR replication were confirmed by sequence analysis.

**Northern Blot Analysis**—Adult and fetal human multiple tissue Northern blots (Clontech, Palo Alto, CA) were hybridized, according to the manufacturer's instructions, using a radiolabeled cDNA insert from a *Kpn*I/*Xba*I digestion of pcDNA3-ICE-LAP3.

**Cell Lines, TNF, and Anti-Fas Antibody**—MCF7 cells, BJAB cells, and derived vector, CrmA and CrmA mutant stable transfectants were described previously (17, 30). Jurkat cells were maintained in RPMI 1640 medium with 10% heat-inactivated fetal bovine serum (Hyclone), L-glutamine, penicillin/streptomycin, and nonessential amino acids. Recombinant TNF (specific activity,  $6.27 \times 10^7$  units/mg) was purchased from Genentech (South San Francisco, CA). Anti-Fas (anti-APO-1) antibody was kindly provided by Dr. P. H. Krammer (31).

**Preparation of Cells for Analysis of ICE-LAP3 Processing**—Jurkat cells, BJAB cells, and derived BJAB transfectants were aliquoted at a concentration of  $5 \times 10^3$ /ml into T50 tissue culture flasks (Falcon), with 10 ml of medium in each flask. The following day, cells were treated with anti-Fas antibody (100 ng/ml) plus protein X (10  $\mu$ g/ml) (Sigma) for the indicated time periods, and cells were harvested by centrifugation

and washed once with PBS and lysed in 1 ml of PBS-TDS lysis buffer (0.38 mM NaCl, 2.7 mM KCl, 8.1 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.5 mM KH<sub>2</sub>PO<sub>4</sub>, 1% Triton X-100, 0.5% deoxycholic acid, 0.1% SDS) plus protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 0.5 mg/ml aprotinin, 0.5 mg/ml antipain, and 0.5 mg/ml pepstatin).

MCF7 cells and derived transfectants were plated in 150-mm dishes and grown to 80% confluence. Cells were treated with TNF (40 ng/ml) for 22 h, harvested by scraping, recovered by centrifugation, washed once with PBS, and lysed as above.

**Immunoprecipitation and Western Blot Analysis**—Polyclonal anti-ICE-LAP3 antibody was generated by immunizing rabbits with the synthetic peptide KPD RSSFVPSLFSKKKKN, corresponding to the N-terminal portion of the putative p20 subunit of ICE-LAP3 and conjugated to diphtheria toxin (Chiron, San Diego, CA). Immunoprecipitation and Western analysis were performed as described previously (32). The anti-ICE-LAP3 antiserum was used at a dilution of 1:100 for immunoprecipitation and 1:1000 for Western analysis. The secondary antibody, an anti-rabbit immunoglobulin labeled with horseradish peroxidase, was used at a dilution of 1:10,000. Visualization of the signal was by ECL (Amersham Corp.).

**Immunostaining**—293T cells were grown to 80% confluence on gelatin-coated glass coverslips while  $1 \times 10^5$  Jurkat cells were cytocentrifuged onto glass slides. Cells were fixed and permeabilized with 100% methanol at -20 °C for 10 min. The cells were subsequently washed with PBS and incubated with either a 1:100 dilution of preimmune serum, anti-LAP3 antiserum, or peptide-blocked anti-LAP3 antiserum. After the PBS wash, cells were incubated with 1:1000 fluorescein isothiocyanate anti-rabbit antibody (Sigma) and subsequently washed with PBS and visualized by fluorescence microscopy (33).

**Cell Death Assay**—MCF7 cells were transiently transfected as described previously (33). Briefly,  $2.5 \times 10^5$  MCF7 cells were transfected with 0.25  $\mu$ g of the reporter plasmid pCMV  $\beta$ -galactosidase plus 1.5  $\mu$ g of test plasmid in 6-well tissue culture dishes using Lipofectamine as per the manufacturer's instructions. The transfection was carried out in 1 ml of Opti-MEM minimal medium (Life Technologies, Inc.), and after 5 h, 1 ml of serum-containing growth medium was added. Two days later, the cells were fixed with 0.5% glutaraldehyde and stained with 5-bromo-4-chloro-3-indoyl  $\beta$ -D-galactosidase for 4 h. Cells were visualized by phase-contrast microscopy. At least 300  $\beta$ -galactosidase-positive cells were counted for each transfection ( $n = 3$ ) and identified as apoptotic or nonapoptotic based on morphological alterations typical of adherent cells undergoing apoptosis including becoming rounded, condensed, and detaching from the dish (2).

## RESULTS AND DISCUSSION

**Cloning of ICE-LAP3**—The Human Genome Sciences human cDNA data base was searched for genes related to ICE/ced-3. Six cDNAs related to the ICE/ced-3 gene family were isolated, and all except one were previously described (10, 17, 19–25). In this report, we characterize a 2.4-kilobase cDNA that contains an open reading frame beginning with an initiator methionine (34) and ending 912 nucleotides later at an Opal codon. Given the presence of an in-frame stop codon 285 base pairs upstream of the initiator methionine and the size of the transcript (2.4 kilobases; see Fig. 1A), it is likely that the full-length coding sequence was identified. This gene encodes a previously undescribed protein of 304 amino acids with a predicted molecular mass of 35 kDa, designated ICE-LAP3 (Fig. 1A).

**ICE-LAP3 Is a Novel Member of the ICE/ced-3 Gene Family**—A BLAST search of the GenBank protein data base revealed that the predicted protein sequence of ICE-LAP3 is similar to the *C. elegans* Ced-3 protein and classifies ICE-LAP3 as a novel member of the ICE/ced-3 gene family. Of the family members thus far cloned, ICE-LAP3 is the most closely related homologue to the mammalian cell death effector, Yama/CPP32/Apopain (17, 20, 21). ICE-LAP3 has 58% sequence identity (75% similarity) with Yama, 40% identity (57% similarity) with Mch2 $\alpha$ , and less than 35% identity (55% similarity) with the other ICE/Ced-3 family members. Like Yama, ICE-LAP3 is highly homologous to Ced-3, sharing 35% sequence identity (54% similarity).

Yama is an Asp-specific cysteine protease responsible for the cleavage of the death substrate PARP (17, 21). The full-length

**A**

MADOUCC~~E~~QCVFDSANEDPSVDA~~Q~~~~A~~~~P~~~~S~~~~E~~~~T~~~~F~~~~L~~~~K~~~~V~~~~W~~~~C~~~~I~~~~N~~  
 SDRVPTYK~~D~~~~O~~~~N~~~~F~~~~E~~~~L~~~~G~~~~C~~~~I~~~~T~~~~R~~~~N~~~~R~~~~F~~~~O~~~~X~~~~T~~~~C~~~~G~~~~V~~~~R~~~~N~~~~G~~~~T~~~~K~~~~D~~~~A~~~~E~~~~A~~~~L~~~~F~~~~C~~  
 SLC~~G~~~~F~~~~V~~~~T~~~~Y~~~~N~~~~D~~~~C~~~~A~~~~H~~~~O~~~~L~~~~A~~~~K~~~~S~~~~E~~~~H~~~~T~~~~N~~~~A~~~~T~~~~C~~~~A~~~~T~~  
 GVT~~P~~~~I~~~~X~~~~D~~~~T~~~~A~~~~M~~~~R~~~~D~~~~R~~~~C~~~~X~~~~T~~~~I~~~~L~~~~E~~~~P~~~~K~~~~F~~~~I~~~~T~~~~E~~~~T~~~~D~~~~D~~~~O~~~~I~~~~A~~~~D~~~~S~~~~G~~~~P~~~~I~~~~N~~~~D~~  
 ANPRYK~~I~~~~P~~~~V~~~~E~~~~A~~~~D~~~~F~~~~A~~~~Y~~~~S~~~~T~~~~V~~~~G~~~~T~~~~Y~~~~S~~~~W~~~~R~~~~S~~~~P~~~~G~~~~G~~~~S~~~~W~~~~F~~~~V~~~~O~~~~A~~~~L~~~~C~~~~S~~~~I~~~~E~~~~S~~~~I~~  
 NO~~I~~~~L~~~~T~~~~R~~~~V~~~~N~~~~D~~~~R~~~~A~~~~H~~~~F~~~~E~~~~S~~~~Q~~~~S~~~~O~~~~O~~~~M~~~~F~~~~H~~~~E~~~~X~~~~X~~~~K~~~~O~~~~C~~~~V~~~~S~~~~N~~~~L~~~~T~~~~K~~~~E~~~~L~~~~Y~~~~F~~~~S~~~~O~~

**B**

	Yama/CPP32/Apopain	ICE-LAP3	ICE/Ced-3	ICE rel II/TX/ICH2	ICE rel III	ICH1
Yama/CPP32/Apopain		GLRKY	LSHGE	PIAACRGTE	CTTSMRSPCRGIVWVF	
Mch2α		TSRGT	LSHGE	PIAACRGTE	CTTSMRSPCRGIVWVF	
CED-3		PERUT	LSHGE	PIAACRGNQ	CTTSMRSPCRGIVWVF	
ICE		PTRCT	LSHGE	PIAACRGR	CTTSMRSPCRGIVWVF	
ICE rel II/TX/ICH2		PRNTCA	HSNGIR	PIAACRGS	DNVSWEETPTNGSVF	
ICE rel III		PPRICA	HSNGIL	PIAACRCAN	HNVSWEETPTNGSVF	
ICH1		PAANGA	HSNGIL	PIAACRCGX	HNVSWEETPTACGSVII	
	EFNSCC	LSHGE	PIAACRGDE	CTTSMRSPCRGIVWVF		


**C**

FIG. 1. Sequence analysis of ICE-LAP3. **A**, deduced amino acid sequence of ICE-LAP3. The conserved pentapeptide QACRG is boxed. Putative Asp cleavage sites are indicated with an asterisk. The underlined sequence corresponds to the synthetic peptide used to generate anti-ICE-LAP3 antibody. **B**, sequence alignment of known members of the human ICE/Ced-3 family and the nematode gene ced-3. The pentapeptide QACRG is boxed. Based on the x-ray crystal structure of ICE, the residues involved in catalysis and substrate binding are shown in color, and the numbers correspond to the position of residues within ICE. Red-filled circles are catalytic; green-filled triangles represent the binding pocket for the carboxylate side chain of the P<sub>1</sub> aspartic acid. Blue-filled squares indicate the residues adjacent to the P<sub>2</sub>-P<sub>4</sub> amino acids. **C**, phylogenetic analysis of the ICE/ced-3 gene family.

p32 form, or Pro-Yama, requires proteolytic processing to active p17 and p12 subunits (21). The majority of sequence homology between Yama and ICE-LAP3 lies within a region of ICE-LAP3 that corresponds to the active subunits of Yama. Comparison with Yama would suggest that ICE-LAP3 contains an N-terminal aspartate cleavage site and an internal cleavage site defining two subunits that are not separated by a linker peptide (Fig. 1A). The QACRG pentapeptide, conserved in all family members, is likewise conserved in ICE-LAP3. In addition, based on the x-ray crystal structure of ICE (35, 36), the amino acid residues His<sup>237</sup>, Gly<sup>238</sup>, and Cys<sup>235</sup> of ICE are involved in catalysis, while the residues Arg<sup>179</sup>, Gln<sup>233</sup>, and Arg<sup>241</sup> form a binding pocket for the carboxylate side chain of the P<sub>1</sub> aspartic acid. These six amino acids are conserved in all ICE/Ced-3 family members including ICE-LAP3 (Fig. 1B). However, residues that form the P<sub>2</sub>-P<sub>4</sub> binding pockets are not widely conserved among family members, suggesting that they may determine substrate specificity.

Phylogenetic analysis of the ICE/ced-3 gene family revealed three subfamilies (Fig. 1C). Yama/CPP32/Apopain, ICE-LAP3, and Mch2 are closely related to *C. elegans* Ced-3 and comprise the Yama subfamily. ICE and the ICE-related genes, TX/ICH2 and ICE rel III, form the ICE subfamily, while ICH1 and its mouse homologue, Nedd-2, form the Nedd-2 subfamily.

**Distribution of ICE-LAP3**—Northern blot analysis revealed that ICE-LAP3 is constitutively expressed in a variety of fetal and adult human tissues with small amounts in the fetal brain (Fig. 2A). The mRNA transcript is approximately 2.4 kilobases,




**A****B****C**  
J  
U  
r  
k  
a  
t

FIG. 2. ICE-LAP3 expression and subcellular localization. **A**, a human adult and fetal tissue poly(A)<sup>+</sup> Northern blot (Clontech) was probed with <sup>32</sup>P-labeled ICE-LAP3 cDNA. **PBL**, peripheral blood leukocyte. **B**, a variety of human cell lines were examined for expression of endogenous ICE-LAP3 protein. Cell lysates were immunoprecipitated (**IP**) with anti-ICE-LAP3 antibody (**Y**) or control pre-immune serum (**C**) and immunoblotted with anti-ICE-LAP3 antibody. **C**, immunolocalization of ICE-LAP3 using the anti-LAP3 polyclonal antisera. Anti-LAP3 reactivity was visualized with fluorescein isothiocyanate-conjugated anti-rabbit secondary antibody. Jurkat T cells were stained with peptide-blocked anti-LAP3 serum (left) and anti-LAP3 serum (right).

consistent with the size of the cDNA clones isolated. Using a rabbit anti-peptide antibody directed against ICE-LAP3, a variety of cell lines were examined for expression of ICE-LAP3 protein, which was detected to a variable extent in all cell lines analyzed (Fig. 2B). Endogenous ICE-LAP3 migrated at approximately 35 kDa, consistent with the predicted molecular mass.

**Cellular Localization of ICE-LAP3**—Intracellular localization of endogenous ICE-LAP3 was determined using the above described anti-LAP3 antibody. In Jurkat T cells, ICE-LAP3 localized diffusely to the cytoplasm and juxtamembrane structures (Fig. 2C). Similar results were obtained using 293T cells (data not shown). The specificity of this staining was confirmed using preimmune serum and peptide-blocked anti-LAP3 serum. This is the first reported immunolocalization of an endogenous ICE/Ced-3 family member and is consistent with previous reports suggesting that the death effector machinery resides within the cytoplasm and not in the nucleus (37).

**Overexpression of ICE-LAP3 in MCF7 Cells Induces Apoptosis**—All ICE/Ced-3 family members have been shown to induce apoptosis when overexpressed in various cell lines. To determine whether ICE-LAP3 may have a role in cell death, an expression construct encoding the full-length protein was transfected into MCF7 breast carcinoma cells and subsequently assessed for apoptotic features. Unlike full-length ICE, expression of full-length ICE-LAP3 failed to induce apoptosis (data not shown). However, expression of a truncated derivative of ICE-LAP3 (pcDNA3 AU1-ICE-LAP3 p28), which lacked 53 N-terminal amino acids corresponding to the putative pro-domain, caused cell death (Fig. 3A). The ICE-LAP3 p28-transfected cells displayed morphological alterations typical of adherent cells undergoing apoptosis, becoming rounded, condensed, and detaching from the dish (Fig. 3B). The nuclei of the rounded MCF7 cells exhibited apoptotic morphology as assessed by propidium iodide staining (data not shown). To determine whether the amino acid residue Cys<sup>186</sup>, corresponding to the catalytic Cys<sup>235</sup> of ICE, was essential for apoptotic activity, a mutant of ICE-LAP3 was generated in which the cysteine

## Characterization of ICE-LAP3




FIG. 3. ICE-LAP3 induces apoptosis and is activated during Fas- and TNF-induced cell death. **A**, MCF7 cells were transiently transfected with the reporter gene  $\beta$ -galactosidase and either the truncated form of ICE-LAP3 (p28) or the mutant version with the catalytic cysteine residue inactivated (ICE-LAP3 mutant), ICE, or a vector control as described under "Materials and Methods." Percent apoptotic cells represents the mean value from three independent experiments (mean  $\pm$  S.D.). **B**, transfected cells were stained with 5-bromo-4-chloro-3-indoyl  $\beta$ -D-galactoside and examined by phase contrast microscopy. **C**, a time course of pro-ICE-LAP3 proteolytic processing generating an active p20 subunit during Fas-induced apoptosis of BJAB and Jurkat cells.  $5 \times 10^6$  BJAB or Jurkat cells were treated with anti-Fas antibody (100 ng/ml) plus protein A (10  $\mu$ g/ml) for the indicated time periods, and cell lysates were analyzed by immunoprecipitation and Western blot analysis with anti-ICE-LAP3 antiserum. **D**, activation of ICE-LAP3 during anti-Fas and TNF treatment is blocked by CrmA. Cells were treated with anti-Fas antibody or TNF and prepared as in **C**. *Left panel*,  $5 \times 10^6$  BJAB cells or derived transfectants were treated with anti-Fas antibody (100 ng/ml) plus protein A (10  $\mu$ g/ml) for 6 h. *Right panel*, MCF7 or derived transfectants were treated with TNF (40 ng/ml) for 22 h.

residue was altered to an alanine. Overexpression of the mutant form of ICE-LAP3 did not induce apoptotic changes in MCF7 cells (Fig. 3, A and B). Taken together, these results suggest that the activity of ICE-LAP3 is tightly regulated in mammalian cells and that activation of ICE-LAP3 likely requires removal of the pro-domain. This is consistent with the finding that overexpression of the pro-form of Yama (Pro-Yama) in MCF7 cells also failed to induce cell death (data not shown).

**ICE-LAP3 Is Activated during Fas- and TNF-induced Apoptosis**—Two cell surface cytokine receptors, Fas/APO-1 and the p55 receptor for tumor necrosis factor (TNFR-1), have been shown to trigger apoptosis by their respective natural ligands or specific agonist antibodies (30). To determine whether ICE-LAP3 may be a component of the Fas- and TNF-induced cell death pathways, concomitant processing of endogenous pro-ICE-LAP3 was assessed. Over a time course of incubation with anti-Fas antibody, pro-ICE-LAP3 was processed to form p20 and p12 subunits in both Jurkat T cells and BJAB B cells (the anti-LAP3 antibody generated was directed against the p20 subunit, which could therefore be detected) (Fig. 3C). Similar results were observed during TNF-induced cell death of MCF7 cells (Fig. 3D). CrmA, a poxvirus gene product, has been shown to potently block both Fas- and TNF-induced cell death (30). Engagement of Fas and TNFR in CrmA-expressing cells abrogated ICE-LAP3 activation as well as cell death (Fig. 3D) (30). As expected, ICE-LAP3 was processed in inactive mutant CrmA (17) expressing cell lines (Fig. 3D).

In conclusion, we have identified a novel death-inducing protein of the ICE/Ced-3 family. ICE-LAP3 was immunolocalized to the cytoplasm, where the death effector machinery is thought to reside (37). This is the first report describing the activation of an endogenous ICE/Ced-3 cysteine protease during Fas- and TNF-induced cell death, suggesting that it is a mediator of the cytokine-mediated cell death pathway. Further, there is compelling evidence that a family member, Yama, acts as a distal effector of the cell death pathway (17, 21). The high homology between Yama and ICE-LAP3 is intriguing and raises many important questions about a potential role of ICE-LAP3 in a general cell death program. One possibility is that ICE-LAP3 also acts as an effector in a redundant cell death pathway distinct from the one utilizing Yama. Alternatively, ICE-LAP3 could act as an upstream enzyme, or "Yama convertase," responsible for the processing of Pro-Yama to an active death protease. The cloning and characterization of the Yama-related protein ICE-LAP3 will help address these specific questions and, in general, enhance our understanding of the cell death machinery and the proteases that compose it.

**Acknowledgments**—We are grateful to Dr. Peter H. Krammer (Heidelberg, Germany) for kindly providing anti-APO-1 antibody and Zhiwu Lin, Muneeb Tewari, and Karen O'Rourke for technical assistance. The initial EST clones used in this study were discovered as part of a joint collaboration between scientists at The Institute for Genomic Research and at Human Genome Sciences. We thank Ian M. Jones for help in preparing the figures.

## REFERENCES

- Ellis, R. E., Yuan, J. Y., and Horwitz, H. R. (1991) *Annu. Rev. Cell Biol.* 7, 663–698
- Cohen, J. J. (1993) *Immunol. Today* 14, 126–130
- Thompson, C. (1995) *Science* 267, 1456–1462
- Bart, P. J., and Tomei, L. D. (1994) *Bio/Technology* 12, 487–493
- Kerr, J. F. R., Winterford, C. M., and Harmon, B. V. (1994) *Cancer (Phila.)* 73, 2013–2023
- Ellis, H. M., and Horwitz, H. R. (1986) *Cell* 44, 817–829
- Yuan, J. Y., and Horwitz, H. R. (1990) *Dev. Biol.* 138, 33–41
- Hengartner, M. O., Ellis, R. E., and Horwitz, H. R. (1992) *Nature* 356, 494–499
- Vaux, D. L., Weissman, I. L., and Kim, S. K. (1992) *Science* 258, 1955–1957
- Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M., and Horwitz, H. R. (1993) *Cell* 75, 641–652
- Thornberry, N. A., Bull, H., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J.,

- Elliston, K. O., Ayala, J. M., Casano, F. J., Chin, J., Ding, G. J.-F., Egger, L. A., Gaffney, E. P., Limjoco, G., Palyha, O. C., Raju, S. M., Rolando, A. M., Salley, J. P., Yamin, T. T., Lee, T. D., Shively, J. E., MacCross, M., Mumford, R. A., Schmidt, J. A., and Tocci, M. J. (1992) *Nature* 356, 768-774.
12. Cerretti, D. P., Kozlosky, C. J., Mosley, B., Nelson, N., Ness, K. V., Greenstreet, T. A., March, C. J., Kronheim, S. R., Druck, T., Cannizzaro, L. A., Huebner, K., and Black, R. A. (1992) *Science* 256, 97-100.
13. Miura, M., Zhu, H., Rotello, R., Hartwig, E. A., and Yuan, J. (1993) *Cell* 75, 653-660.
14. Li, P., Allen, H., Banerjee, S., Franklin, S., Herzog, L., Johnston, C., McDowell, J., Paskind, M., Rodman, L., Salfeld, J., Towne, E., Tracey, D., Wardwell, S., Wei, F.-Y., Wong, W., Kamen, R., and Seshadri, T. (1995) *Cell* 80, 401-411.
15. Kuida, K., Lippke, J. A., Ku, G., Harding, M. W., Livingston, D. J., Su, M. S.-S., and Flavell, R. A. (1995) *Science* 267, 2000-2003.
16. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) *Nature* 371, 346-347.
17. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. (1995) *Cell* 81, 801-809.
18. Kumar, S., Kinoshita, M., Noda, M., Copeland, N. G., and Jenkins, N. A. (1994) *Genes & Dev.* 8, 1613-1626.
19. Wang, L., Miura, M., Bergeron, L., Zhu, H., and Yuan, J. (1994) *Cell* 78, 739-750.
20. Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. S. (1994) *J. Biol. Chem.* 269, 30761-30764.
21. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T. T., Yu, V. L., and Miller, D. K. (1995) *Nature* 376, 37-43.
22. Munday, N. A., Vaillancourt, J. P., Ali, A., Casano, F. J., Miller, D. K., Molineaux, S. M., Yamin, T. T., Yu, V. L., and Nicholson, D. W. (1995) *J. Biol. Chem.* 270, 15870-15876.
23. Faucheu, C., Diu, A., Chan, A. W., Blanchet, A. M., Miossec, C., Hervé, F., Collard-Dutilleul, V., Gu, Y., Aldape, R. A., Lippke, J. A., Rocher, C., Su, M. S. S., Livingston, D. J., Hercend, T., and Lalanne, J. L. (1995) *EMBO J.* 14, 1914-1922.
24. Kamens, J., Paskind, M., Hugunin, M., Talanian, R. V., Allen, H., Bansch, D., Bump, N., Hackett, M., Johnston, C. G., Li, P., Mankovich, J. A., Terranova, M., and Chayer, T. (1995) *J. Biol. Chem.* 270, 15250-15256.
25. Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. S. (1995) *Cancer Res.* 55, 2737-2742.
26. Darmon, A. J., Nicholson, D. W., and Bleackley, R. C. (1995) *Nature* 377, 446-448.
27. Adams, M. D., Kelley, J. M., Gocayne, J. D., Dubnick, M., Polymeropoulos, M. H., Xiao, H., Merril, C. R., Wu, A., Olde, B., Moreno, R. F., Kerlavage, A. R., McCombie, W. R., and Venter, J. C. (1991) *Science* 252, 1651-1656.
28. Adams, M. D., Dubnick, M., Kerlavage, A. R., Moreno, R., Kelley, J. M., Utterback, T. R., Nagle, J. W., Fields, C., and Venter, J. C. (1992) *Nature* 355, 632-634.
29. Higuchi, R., Krummel, B., and Saiki, R. K. (1988) *Nucleic Acids Res.* 16, 7351-7367.
30. Tewari, M., and Dixit, V. M. (1995) *J. Biol. Chem.* 270, 3255-3260.
31. Trauth, B. C., Klas, C., Peters, A. M. J., Matzku, S., Moller, P., Falk, W., Debactin, K.-M., and Krammer, P. H. (1989) *Science* 245, 301-305.
32. O'Rourke, K. M., Laherty, C. D., and Dixit, V. M. (1992) *J. Biol. Chem.* 267, 24921-24924.
33. Chinnaiyan, A. M., O'Rourke, K., Tewari, M., and Dixit, V. M. (1995) *Cell* 81, 505-512.
34. Kozak, M. (1989) *J. Cell Biol.* 108, 229-241.
35. Wilson, K. P., Black, J.-A. F., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A., Murcko, M. A., Chambers, S. P., Aldape, R. A., Raybuck, S. A., and Livingston, D. J. (1994) *Nature* 370, 270-275.
36. Walker, N. P. C., Talanian, R. V., Brady, K. D., Dang, L. C., Bump, N. J., Ferenz, C. R., Franklin, S., Ghayur, T., Hackett, M. C., Hammill, L. D., Herzog, L., Hugunin, M., Houy, W., Mankovich, J. A., McGuiness, L., Orlewicz, E., Paskind, M., Pratt, C. A., Reis, P., Summani, A., Terranova, M., Welch, J. P., Xiong, L., Moller, A., Tracey, D. E., Kamen, R., and Wong, W. W. (1994) *Cell* 78, 343-352.
37. Raff, M. C., Barres, B. A., Burne, J. F., Coles, H. S., Ishizaki, Y., and Jacobson, M. D. (1994) *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 345, 265-268.